Rhodes Pharmaceuticals LLC announced that the U.S. Food and Drug Administration has granted approval for the **DILAUDID** (Hydromorphone Hydrochloride) oral solution, keeping the product available for clinical use. This regulatory action aims to secure the supply chain and stabilize market availability amidst prevailing shortages of the narcotic analgesic.